IP Library › Granted Patent US 12,297,271
Granted Patent B2
US 12,297,271 · App. 18/589,536 · Granted May 13, 2025

PD-1 single domain antibodies and therapeutic compositions thereof

Inventors: Rajay A. Pandit (La Jolla, CA); John C. Timmer (San Diego, CA); Angelica N. Sanabria (La Jolla, CA); Florian Sulzmaier (San Diego, CA); Brendan P. Eckelman (Encinitas, CA)
Assignee: Inhibrx Biosciences, Inc.
C07K16/2818C07K16/2812C07K16/2815C07K16/2866C07K16/30C07K2317/24C07K2317/31C07K2317/565C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,297,271
App. No.
18/589,536
Granted
May 13, 2025
Kind
B2
Abstract

Provided herein are binding polypeptides that specifically bind PD-1. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind PD-1. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided PD-1 binding polypeptides for treating diseases and conditions, such as cancer.

Claims (18)

1. A method of stimulating or inducing an immune response in a subject, the method comprising administering, to a subject in need thereof, a PD-1-binding polypeptide construct comprising at least one heavy chain only variable domain (PD-1 VHH domain) that specifically binds PD-1, wherein the at least one PD-1 VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 301 or 313, a CDR2 comprising the amino acid sequence of SEQ ID NO: 305 or 314, and a CDR3 comprising the amino acid sequences set forth in SEQ ID NO: 309 or 315.

2. The method of claim 1 , wherein the PD-1 binding polypeptide construct comprises one or more additional binding domain that binds to a target other than PD-1.

3. The method of claim 2 , wherein the one or more additional binding domains binds a co-stimulatory molecule.

4. The method of claim 3 , wherein the co-stimulatory molecule is 41BB, OX40, GITR, ICOS, or CD28.

5. The method of claim 2 , wherein the one or more additional binding domains binds an immune checkpoint other than PD-1.

6. The method of claim 2 , wherein the one or more additional binding domains binds to an activating receptor on an immune cell.

7. The method of claim 2 , wherein the one or more additional binding domains binds to a tumor associated antigen (TAA).

8. The method of claim 1 , wherein the PD-1 VHH domain that specifically binds PD-1, blocks the interaction of PD-1 and PD-L1.

9. The method of claim 1 , wherein the polypeptide comprises an immunoglobulin Fc region.

10. The method of claim 1 , wherein the at least one PD-1 VHH domain comprises an amino acid sequence at least 85%, identical to the amino acid sequence of SEQ ID NO: 312 and binds PD-1.

11. The method of claim 1 , wherein the at least one PD-1 VHH domain comprises the amino acid sequence of SEQ ID NO: 312.

12. The method of claim 1 , wherein the PD-1 binding polypeptide is a single domain antibody.

13. A method of treating cancer in a subject, the method comprising administering, to a subject in need thereof, a therapeutically effective amount of a PD-1-binding polypeptide construct, comprising at least one heavy chain only variable domain (PD-1 VHH domain) that specifically binds PD-1, wherein the at least one PD-1 VHH domain comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 301 or 313, a CDR2 comprising the amino acid sequence of SEQ ID NO: 305 or 314, and a CDR3 comprising the amino acid sequences set forth in SEQ ID NO: 309 or 315.

14. The method of claim 13 , wherein the PD-1 binding polypeptide construct comprises one or more additional binding domain that binds to a target other than PD-1.

15. The method of claim 13 , wherein the polypeptide comprises an immunoglobulin Fc region.

16. The method of claim 13 , wherein the at least one PD-1 VHH domain comprises an amino acid sequence at least 85%, identical to the amino acid sequence of SEQ ID NO: 312 and binds PD-1.

17. The method of claim 13 , wherein the at least one PD-1 VHH domain comprises the amino acid sequence of SEQ ID NO: 312.

18. The method of claim 13 , wherein the PD-1 binding polypeptide is a single domain antibody.

Assignments (3)
SECURITY INTEREST Recorded Jan 14, 2025
From: INHIBRX BIOSCIENCES, INC.
To: OXFORD FINANCE LLC; OXFORD FINANCE LLC
Reel/Frame 069894/0045 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2024
From: INHIBRX, INC.
To: INHIBRX BIOSCIENCES, INC.
Reel/Frame 067679/0635 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2024
From: PANDIT, RAJAY A.; TIMMER, JOHN C.; SANABRIA, ANGELICA N.; SULZMAIER, FLORIAN; ECKELMAN, BRENDAN P.
To: INHIBRX, INC.
Reel/Frame 066819/0469 →
Continuity (5)
Division 17524016 · Nov 11, 2021
Division 16600298 · Oct 11, 2019
Provisional Application 62791152 · Jan 11, 2019
Provisional Application 62744615 · Oct 11, 2018
Related Publication 20240317860A1 · Sep 26, 2024
References Cited (267)
US 4522811A · Eppstein et al. · 1985 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4832959A · Engels et al. · 1989 [cited by applicant]
US 5258498A · Huston et al. · 1993 [cited by applicant]
US 5500362A · Robinson et al. · 1996 [cited by applicant]
US 5525491A · Huston et al. · 1996 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5834597A · Tso et al. · 1998 [cited by applicant]
US 6054297A · Carter et al. · 2000 [cited by applicant]
US 6120762A · Johnson et al. · 2000 [cited by applicant]
US 6132992A · Ledbetter et al. · 2000 [cited by applicant]
US 6982321B2 · Winter · 2006 [cited by applicant]
US 7087409B2 · Barbas, III et al. · 2006 [cited by applicant]
US 7183076B2 · Arathoon et al. · 2007 [cited by applicant]
US 7381803B1 · Weiner et al. · 2008 [cited by applicant]
US 7527791B2 · Adams et al. · 2009 [cited by applicant]
US 7635475B2 · Kumagai et al. · 2009 [cited by applicant]
US 7728114B2 · Mach et al. · 2010 [cited by applicant]
US 7959925B2 · Weinberg et al. · 2011 [cited by applicant]
US 7994289B2 · Waldmann et al. · 2011 [cited by applicant]
US 7998469B2 · Gantier et al. · 2011 [cited by applicant]
US 8044178B2 · Boghaert et al. · 2011 [cited by applicant]
US 8052964B2 · Gantier et al. · 2011 [cited by applicant]
US 9006399B2 · Liu et al. · 2015 [cited by applicant]
US 9035026B2 · Hoffman et al. · 2015 [cited by applicant]
US 9605084B2 · Moore et al. · 2017 [cited by applicant]
US 9644016B2 · Stagliano et al. · 2017 [cited by applicant]
US 9650446B2 · Moore et al. · 2017 [cited by applicant]
US 9701750B2 · Hoffman et al. · 2017 [cited by applicant]
US 9701759B2 · Desjarlais et al. · 2017 [cited by applicant]
US 9803021B2 · Morrison · 2017 [cited by applicant]
US 10544222B2 · Punnonen et al. · 2020 [cited by applicant]
US 20050123546A1 · Umana et al. · 2005 [cited by applicant]
US 20060270045A1 · Cregg et al. · 2006 [cited by applicant]
US 20110274685A1 · Keler et al. · 2011 [cited by applicant]
US 20110275787A1 · Kufer et al. · 2011 [cited by applicant]
US 20120237498A1 · Ahrens et al. · 2012 [cited by applicant]
US 20130183321A1 · Smith et al. · 2013 [cited by applicant]
US 20140322129A1 · Leong et al. · 2014 [cited by applicant]
US 20140348841A1 · Schebye et al. · 2014 [cited by applicant]
US 20140363426A1 · Moore et al. · 2014 [cited by applicant]
US 20150064204A1 · Beers et al. · 2015 [cited by applicant]
US 20150079088A1 · Lowman et al. · 2015 [cited by applicant]
US 20150087810A1 · Moore et al. · 2015 [cited by applicant]
US 20150239991A1 · Blein et al. · 2015 [cited by applicant]
US 20150307617A1 · Du et al. · 2015 [cited by applicant]
US 20150307628A1 · Kim et al. · 2015 [cited by applicant]
US 20160122425A1 · Daugherty et al. · 2016 [cited by applicant]
US 20160194399A1 · Irving et al. · 2016 [cited by applicant]
US 20160207981A1 · Eckelman et al. · 2016 [cited by applicant]
US 20160280795A1 · Wang · 2016 [cited by applicant]
US 20160289324A1 · Moore et al. · 2016 [cited by applicant]
US 20170022284A1 · Timmer et al. · 2017 [cited by applicant]
US 20170037130A1 · Raum et al. · 2017 [cited by applicant]
US 20170081397A1 · Stagliano et al. · 2017 [cited by applicant]
US 20170137520A1 · Punnonen · 2017 [cited by examiner]
US 20170198050A1 · Eckelman et al. · 2017 [cited by applicant]
US 20170204139A1 · Moore et al. · 2017 [cited by applicant]
US 20170226215A1 · Gray et al. · 2017 [cited by applicant]
US 20170369563A1 · Dubridge et al. · 2017 [cited by applicant]
US 20180016354A1 · Wozniak-Knopp et al. · 2018 [cited by applicant]
US 20180194842A1 · Mach et al. · 2018 [cited by applicant]
US 20180355038A1 · Smith et al. · 2018 [cited by applicant]
CN 107474135A · 2017 [cited by applicant]
EP 219781A2 · 1985 [cited by applicant]
EP 1391213A1 · 2002 [cited by applicant]
WO WO1992008737A1 · 1992 [cited by applicant]
WO WO199404679A1 · 1994 [cited by applicant]
WO WO1998050431A2 · 1998 [cited by applicant]
WO WO200024884A2 · 2000 [cited by applicant]
WO WO2000041474A2 · 2000 [cited by applicant]
WO WO2002079249A2 · 2002 [cited by applicant]
WO WO2002083733A2 · 2002 [cited by applicant]
WO WO2002086156A2 · 2002 [cited by applicant]
WO WO2002095067A2 · 2002 [cited by applicant]
WO WO2002101048A2 · 2002 [cited by applicant]
WO WO2003000896A2 · 2003 [cited by applicant]
WO WO2003023032A2 · 2003 [cited by applicant]
WO WO2004022593A2 · 2004 [cited by applicant]
WO WO2004022747A1 · 2004 [cited by applicant]
WO WO200492219A2 · 2004 [cited by applicant]
WO WO2005035584A1 · 2005 [cited by applicant]
WO WO2005040220A1 · 2005 [cited by applicant]
WO WO2005063816A2 · 2005 [cited by applicant]
WO WO2005100402A1 · 2005 [cited by applicant]
WO WO2006029879A2 · 2006 [cited by applicant]
WO WO2007033230A2 · 2007 [cited by applicant]
WO WO2008119567A2 · 2008 [cited by applicant]
WO WO2009067800A1 · 2009 [cited by applicant]
WO WO2009089004A1 · 2009 [cited by applicant]
WO WO2010151792A1 · 2010 [cited by applicant]
WO WO2011056983A1 · 2011 [cited by applicant]
WO WO2011133886A2 · 2011 [cited by applicant]
WO WO2011143545A1 · 2011 [cited by applicant]
WO WO2012058768A1 · 2012 [cited by applicant]
WO WO2013026837A1 · 2013 [cited by applicant]
WO WO2014067011A1 · 2014 [cited by applicant]
WO WO2014099997A1 · 2014 [cited by applicant]
WO WO2014194100A1 · 2014 [cited by applicant]
WO WO2015001085A1 · 2015 [cited by applicant]
WO WO2015091910A2 · 2015 [cited by applicant]
WO WO2015095392A1 · 2015 [cited by applicant]
WO WO2016177762A1 · 2016 [cited by applicant]
WO WO2016179517A1 · 2016 [cited by applicant]
WO WO2016204966A1 · 2016 [cited by applicant]
WO WO2017015623A2 · 2017 [cited by applicant]
WO WO2017030926A1 · 2017 [cited by applicant]
WO WO2017123650A2 · 2017 [cited by applicant]
WO WO2017123673A2 · 2017 [cited by applicant]
WO WO2017134440A2 · 2017 [cited by applicant]
WO WO2017167672A1 · 2017 [cited by applicant]
WO WO2018027025A1 · 2018 [cited by applicant]
WO 2018050039A1 · 2018 [cited by applicant]
WO WO2018127710A1 · 2018 [cited by applicant]
WO WO2019133761A1 · 2019 [cited by applicant]
WO WO2020077257A1 · 2020 [cited by applicant]
Wang et al., “In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates”, Cancer Immunology Research, vol. 2, No. 9, pp. OF1-OF11, (2014). [cited by applicant]
Ackerman, et al. “Biologic activity in a fragment of recombinant human interferon alpha.” Proc Natl Acad Sci U S A. Feb. 1984;81(4):1045-7. [cited by applicant]
Al-Lazikani, et al. “Standard conformations for the canonical structures of immunoglobulins.” J Mol Biol. Nov. 7, 1997;273(4):927-48. [cited by applicant]
Almagro, JC and Fransson, J. “Humanization of antibodies.” Front Biosci. Jan. 1, 2008;13:1619-33. [cited by applicant]
Alegre, et al. “Effect of a single amino acid mutation on the activating and immunosuppressive properties of a “humanized” OKT3 monoclonal antibody.” J Immunol. Jun. 1, 1992;148(11):3461-8. [cited by applicant]
Anasetti, et al. “Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody.” Transplantation. Nov. 1992;54(5):844-51. [cited by applicant]
Anderson, et al. “Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells.” Proc Natl Acad Sci U S A. Mar. 1990;87(6):2274-8. [cited by applicant]
Arndt, et al. “A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors.” Blood. Oct. 15, 1999;94(8):2562-8. [cited by applicant]
Baca, et al. “Antibody humanization using monovalent phage display.” J Biol Chem. Apr. 18, 1997;272(16):10678-84. [cited by applicant]
Behar, et al. “Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells.” Protein Eng Des Sel. Jan. 2008;21(1):1-10. [cited by applicant]
Beliveau, et al. “Probing the substrate specificities of matriptase, matriptase-2, hepsin and DESC1 with internally quenched fluorescent peptides.” FEBS J. Apr. 2009;276(8):2213-26. doi: 10.1111/j.1742-4658.2009.06950.x. [cited by applicant]
Bruggemann, et al. “Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.” J Exp Med. Nov. 1, 1987;166(5):1351-61. [cited by applicant]
Capel, et al. “Heterogeneity of human IgG Fc receptors.” Immunomethods. Feb. 1994;4(1):25-34. [cited by applicant]
Carter, P. “Bispecific human IgG by design.” J Immunol Methods. Feb. 1, 2001;248(1-2):7-15. [cited by applicant]
Carter, et al. “Humanization of an anti-p185HER2 antibody for human cancer therapy.” Proc Natl Acad Sci U S A. May 15, 1992;89(10):4285-9. [cited by applicant]
Carter, et al. “PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.” Eur J Immunol. Mar. 2002;32(3):634-43. [cited by applicant]
Casset et al. “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design”, BBRC 2003, 307: 198-205 (Year: 2003). [cited by applicant]
Chen, et al. “Fusion protein linkers: property, design and functionality.” Adv Drug Deliv Rev. Oct. 2013;65(10):1357-69. doi: 10.1016/j.addr.2012.09.039. [cited by applicant]
Chen et al. “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen”, J. Mol. Bio. (1999) 293, 865-881 (Year: 1999). [cited by applicant]
Clackson, et al. “Making antibody fragments using phage display libraries.” Nature. Aug. 15, 1991;352(6336):624-8. [cited by applicant]
Clynes, et al. “Fc receptors are required in passive and active immunity to melanoma.” Proc Natl Acad Sci U S A. Jan. 20, 1998;95(2):652-6. [cited by applicant]
Cragg, M.S. and Glennie, M.J. “Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.” Blood. Apr. 1, 2004;103(7):2738-43. [cited by applicant]
Cragg, M.S. “Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts.” Blood. Feb. 1, 2003;101(3):1045-52. [cited by applicant]
Daeron, et al. “Fc receptor biology.” Annu Rev Immunol. 1997;15:203-34. [cited by applicant]
Dall'Acqua, et al. “Antibody humanization by framework shuffling.” Methods. May 2005;36(1):43-60. [cited by applicant]
Dall'Acqua, et al. “Properties of human IgGls engineered for enhanced binding to the neonatal Fc receptor (FcRn).” J Biol Chem. Aug. 18, 2006;281(33):23514-24. [cited by applicant]
Davis, et al. “SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.” Protein Eng De… [cited by applicant]
De Haas, et al. “Fc gamma receptors of phagocytes.” J Lab Clin Med. Oct. 1995;126(4):330-41. [cited by applicant]
Diaz, et al. “Structure of the human type-I interferon gene cluster determined from a YAC clone contig.” Genomics. Aug. 1994;22(3):540-52. [cited by applicant]
Deisenhofer, J. “Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from [cited by applicant]
Dotti, et al. “Design and development of therapies using chimeric antigen receptor-expressing T cells.” Immunol Rev. Jan. 2014;257(1):107-26. doi: 10.1111/imr.12131. [cited by applicant]
Endo, Y. and Sawasaki, T. “High-throughput, genome-scale protein production method based on the wheat germ cell-free expression system.” Biotechnol Adv. Nov. 2003;21(8):695-713. [cited by applicant]
Freeman, et al. “Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.” J Exp Med. Oct. 2, 2000;192(7):1027-34. [cited by applicant]
Gazzano-Santoro, et al. “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody.” J Immunol Methods. Mar. 28, 1997;202(2):163-71. [cited by applicant]
Ghetie, et al. “Increasing the serum persistence of an IgG fragment by random mutagenesis.” Nat Biotechnol. Jul. 1997;15(7):637-40. [cited by applicant]
Ghetie, V and Ward, ES. “FcRn: the MHC class I-related receptor that is more than an IgG transporter.” Immunol Today. Dec. 1997;18(12):592-8. [cited by applicant]
Gunasekaran, et al. “Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.” J Biol Chem. Jun. 18, 2010;285(25):19637-46. doi: 10.107… [cited by applicant]
Golovleva, et al. “Ethnic differences in interferon-alpha allele frequencies.” Hum Hered. Jul.-Aug. 1997;47(4):185-8. [cited by applicant]
Golovleva, et al. “Novel variants of human IFN-alpha detected in tumor cell lines and biopsy specimens.” J Interferon Cytokine Res. Oct. 1997;17(10):637-45. [cited by applicant]
Golovleva, et al. “Polymorphism in the interferon-alpha gene family.” Am J Hum Genet. Sep. 1996;59(3):570-8. [cited by applicant]
Guyer, et al. “Immunoglobulin binding by mouse intestinal epithelial cell receptors.” J Immunol. Aug. 1976;117(2):587-93. [cited by applicant]
Ha, et al. “Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins.” Front Immunol. Oct. 6, 2016;7:394. eCollection 2016. [cited by applicant]
Hermanson, GT. “Amine-Reactive and Sulfhydryl-Reactive Cross-linkers” Bioconjugate Techniques; Academic Press: New York (1996), pp. 234-242. [cited by applicant]
Hayward, et al. “Lysis of CD3 hybridoma targets by cloned human CD4 lymphocytes.” Immunology. May 1988;64(1):87-92. [cited by applicant]
Hawkins, et al. “Phase I evaluation of a synthetic mutant of beta-interferon.” Cancer Res. Nov. 1985;45(11 Pt 2):5914-20. [cited by applicant]
Hellstrom, et al. “Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas.” Proc Natl Acad Sci U S A. Sep. 1986;83(18):7059-63. [cited by applicant]
Hellstrom, et al. “Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside.” Proc Natl Acad Sci U S A. Mar. 1985;82(5):1499-502. [cited by applicant]
Hinton, et al. “Engineered human IgG antibodies with longer serum half-lives in primates.” J Biol Chem. Feb. 20, 2004;279(8):6213-6. [cited by applicant]
Hinman, et al. “Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics.” Cancer Res. Jul. 15, 1993;53(14):3336-42. [cited by applicant]
Holliger, et al. “Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody.” Protein Eng. Mar. 1996;9(3):299-305. [cited by applicant]
Honegger, et al. “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool.” J Mol Biol. Jun. 8, 2001;309(3):657-70. [cited by applicant]
Husain, B. and Ellerman, D. “Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies.” BioDrugs. Oct. 2018;32(5):441-464. doi: 10.1007/s40259-018-0299-9. [cited by applicant]
Hussain, et al. “A new allele of interferon-alpha17 gene encoding IFN-alpha17b is the major variant in human population.” J Interferon Cytokine Res. Jul. 1998;18(7):469-77. [cited by applicant]
Hussain, et al. “Both variant forms of interferon-alpha4 gene (IFNA4a and IFNA4b) are present in the human population.” J Interferon Cytokine Res. Sep. 1997;17(9):559-66. [cited by applicant]
Hussain, et al. “IFN-alpha1a gene is the major variant in the North American population.” J Interferon Cytokine Res. Sep. 2000;20(9):763-8. [cited by applicant]
Hussain, et al. “Interferon-alpha 8b is the only variant of interferon-alpha 8 identified in a large human population.” J Interferon Cytokine Res. Jul. 1996;16(7):523-9. [cited by applicant]
Idusogie, et al. “Engineered antibodies with increased activity to recruit complement.” J Immunol. Feb. 15, 2001;166(4):2571-5. [cited by applicant]
IMGT Scientific Chart (IMGT®, the international ImMunoGeneTics information system®, http://www.imgt.org/IMGTScientificChart/Numbering/Hu_IGHGnber.html (created: May 17, 2001, last updated: Jan. 10, 2013). [cited by applicant]
Ishida, et al. “Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.” EMBO J. Nov. 1992;11(11):3887-95. [cited by applicant]
Jaitin, et al. “Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta.” Mol Cell Biol. Mar. 2006;26(5):1888-97. [cited by applicant]
Jendeberg, et al. “Engineering of Fc(1) and Fc(3) from human immunoglobulin G to analyse subclass specificity for staphylococcal protein A.” J Immunol Methods. Feb. 14, 1997;201(1):25-34. [cited by applicant]
Kalie, et al. “An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities.” J Biol Chem. Apr. 13, 2007;282(15):11602-11. [cited by applicant]
Kaneko, et al. “Optimizing therapeutic antibody function: progress with Fc domain engineering.” BioDrugs. Feb. 1, 2011;25(1):1-11. doi: 10.2165/11537830-000000000-00000. [cited by applicant]
Kashmiri, et al. “SDR grafting—a new approach to antibody humanization.” Methods. May 2005;36(1):25-34. [cited by applicant]
Kipriyanov, et al. “Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.” J Mol Biol. Oct. 15, 1999;293(1):41-56. [cited by applicant]
Kim, et al. “Interferon, alpha 17 (IFNA17) Ile184Arg polymorphism and cervical cancer risk.” Cancer Lett. Jan. 28, 2003;189(2):183-8. [cited by applicant]
Kita, et al. “Determination of interferon-alpha2 allele composition in the genomic DNA from healthy volunteers and leukemic patients in Japan.” J Interferon Cytokine Res. Mar. 1997;17(3):135-40. [cited by applicant]
Kohler, et al. “Continuous cultures of fused cells secreting antibody of predefined specificity.” Nature. Aug. 7, 1975;256(5517):495-7. [cited by applicant]
Klimka, et al. “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning.” Br J Cancer. Jul. 2000;83(2):252-60. [cited by applicant]
Krause, et al. “Signaling by covalent heterodimers of interferon-gamma. Evidence for one-sided signaling in the active tetrameric receptor complex.” J Biol Chem. Jul. 28, 2000;275(30):22995-3004. [cited by applicant]
Lamminmaki et al. “Crystal structure of a recombinant anti-estradiol Fab fragment in complex with 17beta-estradiol”, JBC 2001, 276:36687-36694 (Year: 2001). [cited by applicant]
Latchman, et al. “PD-L2 is a second ligand for PD-1 and inhibits T cell activation.” Nat Immunol. Mar. 2001;2(3):261-8. [cited by applicant]
Ledbetter, et al. “Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and pr… [cited by applicant]
Lazar, et al. “Engineered antibody Fc variants with enhanced effector function.” Proc Natl Acad Sci USA. Mar. 14, 2006;103(11):4005-10. [cited by applicant]
Leaver-Fay, et al. “Computationally Designed Bispecific Antibodies using Negative State Repertoires.” Structure. Apr. 5, 2016;24(4):641-651. doi: 10.1016/j.str.2016.02.013. [cited by applicant]
Lefranc, et al. “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains.” Dev Comp Immunol. Jan. 2003;27(1):55-77. [cited by applicant]
Linge, et al. “Transcription of interferon-alpha 2 alleles from virus-induced human leucocytes and lymphoblastoid cells of African origin.” Biochim Biophys Acta. Dec. 27, 1995;1264(3):363-8. [cited by applicant]
Liu, et al. “Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.” Proc Natl Acad Sci U S A. Aug. 6, 1996;93(16):8618-23. [cited by applicant]
Lundell, et al. “The carboxyl-terminal region of human interferon gamma is important for biological activity: mutagenic and NMR analysis.” Protein Eng. Feb. 1991;4(3):335-41. [cited by applicant]
Lode, et al. “Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma.” Cancer Res. Jul… [cited by applicant]
Maccallum, et al. “Antibody-antigen interactions: contact analysis and binding site topography.” J Mol Biol. Oct. 11, 1996;262(5):732-45. [cited by applicant]
Mandelboim, et al. “Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity.” Proc Natl Acad Sci U S A. May 11, 1999;96(10):5640-4. [cited by applicant]
Mandler, et al. “Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines.” J Natl Cancer Inst. Oct. 4, 2000;92(19):1573-81. [cited by applicant]
Mandler, et al. “Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates.” Bioconjug Chem. Jul.-Aug. 2002;13(4):786-91. [cited by applicant]
Mandler, et al. “Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immunoconjugate.” Bioorg Med Chem Lett. May 15, 2000;10(10):1025-8. [cited by applicant]
Martin, et al. “Modeling antibody hypervariable loops: a combined algorithm.” Proc Natl Acad Sci USA. Dec. 1989;86(23):9268-72. [cited by applicant]
Mccafferty, et al. “Phage antibodies: filamentous phage displaying antibody variable domains.” Nature. Dec. 6, 1990;348(6301):552-4. [cited by applicant]
Mccall, et al. “Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.” Mol Immunol. May 1999… [cited by applicant]
Merchant, et al. “An efficient route to human bispecific IgG.” Nat Biotechnol. Jul. 1998;16(7):677 81. [cited by applicant]
Miller, S. “Protein-protein recognition and the association of immunoglobulin constant domains.” J Mol Biol. Dec. 20, 1990;216(4):965-73. [cited by applicant]
Moore, et al. “A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.” MAbs. Nov.-Dec. 2011;3(6):546-57. doi: 10.4161/mabs.3.6.18123. [cited by applicant]
Moore, et al. “Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions.” MAbs. Mar.-Apr. 2010;2(2):181-9. [cited by applicant]
Nagorsen, et al. “Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.” Exp Cell Res. May 15, 2011;317(9):1255-60. doi: 10.1016/j.yexcr.2011.03.010. [cited by applicant]
Natsume, et al. “Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities.” Cancer Res. May 15, 2008;68(10):3863-72. doi: 10.1158/0008-5472.CAN-07-6297. [cited by applicant]
Nicolaou, et al. “Calicheamicin θ : A Rationally Designed Molecule with Extremely Potent and Selective DNA Cleaving Properties and Apoptosis Inducing Activity.” Agnew, Chem Inti. Ed. Engl, 33: 183-186 (1994). [cited by applicant]
Nyman, et al. “Identification of nine interferon-alpha subtypes produced by Sendai virus-induced human peripheral blood leucocytes.” Biochem J. Jan. 15, 1998;329 ( Pt 2):295-302. [cited by applicant]
Ohigashi, et al. “Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.” Clin Cancer Res. Apr. 15, 2005;11(8):2947-53. [cited by applicant]
Osbourn, et al. “From rodent reagents to human therapeutics using antibody guided selection.” Methods. May 2005;36(1):61-8. [cited by applicant]
Padlan, E.A. “A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties.” Mol Immunol. Apr.-May 1991;28(4-5):489-98. [cited by applicant]
Padlan et al. “Structure of an antibody-antigen complex: crystal structure of the HyHEL-10 Fab-lysozyme complex”, PNAS 1989, 86: 5938-5942 (Year: 1989). [cited by applicant]
Pan, et al. “Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy.” Int J Nanomedicine. May 29, 2018;13:3189-3201. doi: 10.2147/IJN.S164542. eCollection 2018. [cited by applicant]
Pan, et al. “Structural characterization of human interferon gamma. Heterogeneity of the carboxyl terminus.” Eur J Biochem. Jul. 1, 1987;166(1):145-9. [cited by applicant]
Pantel Yushin et al., “Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs”, Cancers , 13, 785, pp. 1-18 (2021). [cited by applicant]
Pascalis et al. “Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody”, The … [cited by applicant]
Petkova, et al. “Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.” Int Immunol. Dec. 2006;18(12):1759-69. [cited by applicant]
Pessano, et al. “The T3/T cell receptor complex: antigenic distinction between the two 20-kd T3 (T3-delta and T3-epsilon) subunits.” EMBO J. Feb. 1985;4(2):337-44. [cited by applicant]
Pestka, S. “Interferon from 1981 to 1986.” Methods Enzymol. 1986;119:3-14. [cited by applicant]
Pestka, S. “The human interferons—from protein purification and sequence to cloning and expression in bacteria: before, between, and beyond.” Arch Biochem Biophys. Feb. 15, 1983;221(1):1-37. [cited by applicant]
Pollard, et al. “Fixation, processing, and immunochemical reagent effects on preservation of T-lymphocyte surface membrane antigens in paraffin-embedded tissue.” J Histochem Cytochem. Nov. 1987;35(11):1329-38. [cited by applicant]
Portolano, et al. “Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by human H and L chain “roulette”.” J Immunol. Feb. 1, 1993;150(3):880-7. [cited by applicant]
Presta, et al. “Humanization of an antibody directed against IgE.” J Immunol. Sep. 1, 1993;151(5):2623-32. [cited by applicant]
Queen, et al. “A humanized antibody that binds to the interleukin 2 receptor.” Proc Natl Acad Sci U S A. Dec. 1989;86(24):10029-33. [cited by applicant]
Ravetch, JV and Kinet, JP. “Fc receptors.” Annu Rev Immunol. 1991;9:457-92. [cited by applicant]
Reusch, et al. “A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.” MAbs. May-Jun. 2014;6(3):728-39. doi: 10.4161/mabs.28591. [cited by applicant]
Riechmann, et al. “Reshaping human antibodies for therapy.” Nature. Mar. 24, 1988;332(6162):323-7. [cited by applicant]
Ridgway, et al. “‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization.” Protein Eng. Jul. 1996;9(7):617-21. [cited by applicant]
Rocca, et al. “Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera.” Br J Cancer. Apr. 5, 2004;90(7):1414-21. [cited by applicant]
Rodrigues, et al. “Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.” Int J Cancer Suppl. 1992;7:45-50. [cited by applicant]
Rohrlich, et al. “HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in response to influenza virus.” Int Immunol. Jun. 2003;15(6):765-72. [cited by applicant]
Rosenberg, et al. “Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.” N Engl J Med. Dec. 22, 1988;319(25):1676-80. [cited by applicant]
Rosok, et al. “A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab.” J Biol Chem. Sep. 13, 1996;271(37):22611-8. [cited by applicant]
Rowland, et al. “Drug localisation and growth inhibition studies of vindesine-monoclonal anti-CEA conjugates in a human tumour xenograft.” Cancer Immunol Immunother. 1986;21(3):183-7. [cited by applicant]
Rudikoff et al. “Single amino acid altering antigen-binding specificity”, Proc Natl Acad Sci USA 1982 vol. 79 p. 1979 (Year: 1982). [cited by applicant]
Running Deer, et al. “High-level expression of proteins in mammalian cells using transcription regulatory sequences from the Chinese hamster EF-1 alpha gene.” Biotechnol Prog. May-Jun. 2004;20(3):880-9. [cited by applicant]
Sadelain, et al. “The basic principles of chimeric antigen receptor design.” Cancer Discov. Apr. 2013;3(4):388-98. doi: 10.1158/2159-8290.CD-12-0548. [cited by applicant]
Sadelain, et al. “The promise and potential pitfalls of chimeric antigen receptors.” Curr Opin Immunol. Apr. 2009;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. [cited by applicant]
Seimetz, et al. “Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.” Cancer Treat Rev. Oct. 2010;36(6):458-67. doi: 10.1016/j.ctrv.2010.03.001. [cited by applicant]
Sims, et al. “A humanized CD18 antibody can block function without cell destruction.” J Immunol. Aug. 15, 1993;151(4):2296-308. [cited by applicant]
Sitaraman, K. and Chatterjee, DK. “High-throughput protein expression using cell-free system.” Methods Mol Biol. 2009;498:229-44. doi: 10.1007/978-1-59745-196-3_15. [cited by applicant]
Shields, et al. “High resolution mapping of the binding site on human IgGI for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.” J Biol Chem. Mar. 2… [cited by applicant]
Spirin, et al. “High-throughput cell-free systems for synthesis of functionally active proteins.” Trends Biotechnol. Oct. 2004;22(10):538-45. [cited by applicant]
Stavenhagen, et al. “Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization.” Adv Enzyme Regul. 2008;48:152-64. doi: 10.1016/j.advenzreg.2007.11.011. [cited by applicant]
Stavenhagen, et al. “Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.” Cancer Res. Sep. 15… [cited by applicant]
UniProt Accession No. P41273: “RecName: Full=Tumor necrosis factor ligand superfamily member 9; AltName: Full=4-1BB ligand; Short=4-1BBL” Oct. 16, 2019 <https://www.ncbi.nlm.nih.gov/protein/P41273>. [cited by applicant]
UniProt Accession No. P23510: “RecName: Full=Tumor necrosis factor ligand superfamily member 4; AltName: Full=Glycoprotein Gp34; AltName: Full=OX40 ligand; Short=OX40L; AltName: Full=TAX transcriptionally-activated glyc… [cited by applicant]
UniProt Accession No. Q9UNG2: “RecName: Full=Tumor necrosis factor ligand superfamily member 18; AltName: Full=Activation-inducible TNF-related ligand; Short=AITRL; AltName: Full=Glucocorticoid-induced TNF-related ligan… [cited by applicant]
UniProt Accession No. P32970: “RecName: Full=CD70 antigen; AltName: Full=CD27 ligand; Short=CD27-L; AltName: Full=Tumor necrosis factor ligand superfamily member 7; AltName: CD_antigen=CD70” Nov. 13, 2019 <https://www.n… [cited by applicant]
Vajdos et al. “Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis”, J. Mol. Biol. (2002) 320, 415-428 (Year: 2002). [cited by applicant]
Van De Winkel, et al. “Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications.” Immunol Today. May 1993;14(5):215-21. [cited by applicant]
Valedkarimi, et al. “Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy.” Biomed Pharmacother. Nov. 2017;95:731-742. doi: 10.1016/j.biopha.2017.07.160. [cited by applicant]
Vivier, et al. “Structure and function of the CD16:zeta:gamma complex expressed on human natural-killer cells.” Int J Cancer Suppl. 1992;7:11-4. [cited by applicant]
Von Kreudenstein, et al. “Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.” MAbs. Sep.-Oct. 2013;5(5):646-54. doi: 10.4161/mabs.25632. [cited by applicant]
Wirthmueller, et al. “Signal transduction by Fc gamma RIII (CD16) is mediated through the gamma chain.” J Exp Med. May 1, 1992;175(5):1381-90. [cited by applicant]
Wu et al. “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues”, J. Mol. Biol. (1999) 294, 151-162 (Year: 1999). [cited by applicant]
Yang, et al. “A common pathway for T lymphocyte activation involving both the CD3-Ti complex and CD2 sheep erythrocyte receptor determinants.” J Immunol. Aug. 15, 1986;137(4):1097-100. [cited by applicant]
Yamamoto, et al. “Creation of interferon-alpha8 mutants with amino acid substitutions against interferon-alpha receptor-2 binding sites using phage display system and evaluation of their biologic properties.” J Interfer… [cited by applicant]
Yokoyama, et al. “How do natural killer cells find self to achieve tolerance?” Immunity. Mar. 2006;24(3):249-57. [cited by applicant]
Young, et al. “Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.” Semin Oncol. Oct. 2014;41(5):623-36. doi: 10.1053/j.seminoncol.2014.08.002. [cited by applicant]
Zalevsky, et al. “Enhanced antibody half-life improves in vivo activity.” Nat Biotechnol. Feb. 2010;28(2):157-9. doi: 10.1038/nbt.1601. [cited by applicant]
Zhao et al. “BTLA identifies dysfunctional PD-1-expressing CD4C T cells in human hepatocellular carcinoma”, Oncoimmunology, 5: 12 e 1254855 (Year: 2016). [cited by applicant]